KROS
KROS clinical trials: Keros Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Keros Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KROS on the catalyst calendar · KROS registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Aug 26, 2028Sponsor estimate | NCT07704099Safety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyKeros Therapeutics, Inc. · Duchenne Muscular Dystrophy | KROSLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Mar 5, 2025Actual | NCT05975905A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary...Keros Therapeutics, Inc. · Pulmonary Arterial Hypertension | KROSLead | Phase 2 | Terminated | Locked | Locked | Locked |
| Aug 29, 2025Sponsor estimate | NCT05927012A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional...Keros Therapeutics, Inc. · Iron Deficiency Anemia | KROSLead | Phase 2 | Withdrawn | Locked | Locked | Locked |
- Primary completion Aug 26, 2028Sponsor estimatePhase 2NCT07704099Safety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyKeros Therapeutics, Inc. · Duchenne Muscular DystrophyRecruitingKROSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 5, 2025ActualPhase 2NCT05975905A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary...Keros Therapeutics, Inc. · Pulmonary Arterial HypertensionTerminatedKROSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2025Sponsor estimatePhase 2NCT05927012A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional...Keros Therapeutics, Inc. · Iron Deficiency AnemiaWithdrawnKROSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner